Evidence map›Paper›PMID 34590284›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2021

Generation of Protein Inhibitors for Validation of Cancer Drug Targets Identified in Functional Genomic Screens.

Sherin McDonald, Arunkumar Annan Sudarsan, Hanan Babeker, Kiranmayee Budharaju, Maruti Uppalapati

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 76% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Sherin McDonaldDepartment of Pathology and Laboratory Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
Arunkumar Annan SudarsanDepartment of Pathology and Laboratory Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
Hanan BabekerDepartment of Pathology and Laboratory Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
Kiranmayee BudharajuDepartment of Pathology and Laboratory Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
Maruti UppalapatiDepartment of Pathology and Laboratory Medicine, University of Saskatchewan, Saskatoon, SK, Canada. maruti.uppalapati@usask.ca.
University of Saskatchewan · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Functional genomic screens can identify several proteins as potential targets for drug development in cancer. Typically, these drug targets are validated with pharmacological inhibition using small molecules. Given that chemical inhibitors do not exist for a many of these proteins, several promising candidates often remain unexplored. In this chapter, we describe methods for generating protein-based inhibitors of intracellular targets using phage display. This is a scalable and inexpensive approach that can be applied to several protein targets identified in genetic screens. We describe methods for expression of target proteins, construction of phage-display libraries and selection of binding proteins. These synthetic binding proteins can block natural protein interactions within the cancer cell and act as inhibitors. Protein inhibitors have utility in validation of drug targets and can also guide small-molecule drug development.

Indexed as

NeoplasmsAntineoplastic AgentsCarrier ProteinsGenomicsHumansPeptide LibraryPharmaceutical PreparationsProteinsAntineoplastic AgentsCarrier ProteinsPeptide LibraryPharmaceutical PreparationsProteinsDrug discoveryFunctional genomicsPhage displayProtein-based inhibitors

Identifiers

PMID34590284
OpenAlexW3203237663

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.